=> d l2
L2 HAS NO ANSWERS
L2 STR



VAR G1=O/S/C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 27 7
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

=> s l2 ful
FULL SEARCH INITIATED 16:28:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5116 TO ITERATE

100.0% PROCESSED 5116 ITERATIONS 1558 ANSWERS
SEARCH TIME: 00.00.01

L5 1558 SEA SSS FUL L2

=> d l7
L7 HAS NO ANSWERS
L7 STR



VAR G1=O/S/C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 27 7
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

=> search l7
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):15
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 16:31:19 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 890 TO ITERATE

100.0% PROCESSED 890 ITERATIONS 168 ANSWERS
SEARCH TIME: 00.00.02

L8 168 SEA SUB=L5 SSS FUL L7

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	41.16	221.51

FILE 'CAPLUS' ENTERED AT 16:31:24 ON 01 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Feb 2006 VOL 144 ISS 6
FILE LAST UPDATED: 31 Jan 2006 (20060131/ED)

=> s l8
L9 19 L8

=> s l9 and py<=2001
21804460 PY<=2001
L10 10 L9 AND PY<=2001

=> d bib abs hitstr 1-10

L10 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:355099 CAPLUS
DN 133:275859
TI QSAR studies on antiasthmatic agents
AU Sachan, Shailja; Bano, Shahnaz; Agrawal, V. K.; Khadikar, P. V.; Srivastava, A. K.
CS Chemistry Department, A.P.S. University, Rewa, 486 003, India
SO National Academy Science Letters (India) (**1999**), 22(7 & 8), 119-124
CODEN: NASLDX; ISSN: 0250-541X
PB National Academy of Sciences, India
DT Journal
LA English
AB Quant. Structure-Activity Relationship (QSAR) studies for a series of antiasthmatic agents have been discussed. Significant correlations of the activity were observed when topol. indexes viz. Szeged Index (Sz), mol. negentropy (N) and first-order valence connectivity index ($^1\chi v$) were coupled with other structural descriptors. Finally, an excellent correlation is obtained by introducing the component of Wiener index i.e. Wd taking care of the double bond contribution.
IT **184107-21-9 184107-25-3 184107-26-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR studies on antiasthmatic agents)
RN 184107-21-9 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184107-25-3 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184107-26-4 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:34903 CAPLUS
DN 130:110279
TI Preparation of N-substituted azaheterocyclic compounds for the clinical treatment of hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role
IN Jorgensen, Tine Krogh; Andersen, Knud Erik; Hohlweg, Rolf; Olsen, Uffe Bang; Fischer, Erik; Polivka, Zdenek; Sindelar, Karel
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9900376	A1	19990107	WO 1998-DK271	19980622 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9879072	A1	19990119	AU 1998-79072	19980622 <--
	EP 991633	A1	20000412	EP 1998-929233	19980622 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002515913	T2	20020528	JP 1999-505221	19980622
	ZA 9805449	A	19990119	ZA 1998-5449	19980623 <--
	US 6054458	A	20000425	US 1998-102863	19980623 <--
	US 6391890	B1	20020521	US 2000-535216	20000327
	US 2002151539	A1	20021017	US 2002-102569	20020314
PRAI	DK 1997-750	A	19970625		
	US 1997-52980P	P	19970707		
	DK 1998-471	A	19980403		
	WO 1998-DK271	W	19980622		
	US 1998-102863	A3	19980623		

US 2000-535216 A3 20000327
OS MARPAT 130:110279
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1, R2 = H, halo, CF3, etc.; X = o-phenylene, O, S, etc.; Y = C, N; m = 1-6; Z = CO2R3, II (wherein R3 = H, C1-6 alkyl)] and their salts, useful for the clin. treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiol. role by eliciting neurogenic pain or inflammation, as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonizing peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity, were prepared and formulated. Thus, reaction of 1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine (preparation given) with Et 3-bromopropionate in the presence of K2CO3 in MeCN followed by hydrolysis of the resulting ester afforded III.HCl which showed 44% inhibition of histamine induced paw edema at 1.0 mg/kg.

IT **134204-78-7P 138248-18-7P 138248-20-1P**
219595-10-5P 219595-14-9P 219595-15-0P
219595-20-7P 219595-33-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-substituted azaheterocyclic compds. for the clin. treatment of hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiol. role)

RN 134204-78-7 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)- (9CI) (CA INDEX NAME)



RN 138248-18-7 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138248-20-1 CAPLUS
CN 1-Piperidineacetic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



RN 219595-10-5 CAPLUS
CN 1-Piperidineacetic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 219595-14-9 CAPLUS
CN 1-Piperidinebutanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



RN 219595-15-0 CAPLUS
CN 1-Piperidinebutanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 219595-14-9
CMF C23 H25 N O2 S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 219595-20-7 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 219595-33-2 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



IT **138248-31-4P 138248-32-5P 219595-50-3P 219595-51-4P 219595-52-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-substituted azaheterocyclic compds. for the clin. treatment of hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiol. role)

RN 138248-31-4 CAPLUS
CN 1-Piperidineacetic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



RN 138248-32-5 CAPLUS
CN 1-Piperidinebutanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



RN 219595-50-3 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 138248-29-0
CMF C24 H27 N O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 219595-51-4 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 219595-52-5 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 219595-51-4
CMF C25 H29 N O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:222210 CAPLUS
DN 126:301606
TI Synthesis and pharmacological evaluation of some amino-acid-containing cyproheptadine derivatives as dual antagonists of histamine H1- and leukotriene D4-receptors
AU Zhang, Mq; Van De Stolpe, A.; Zuiderveld, Op; Timmerman, H.

CS Lieden/Amsterdam Center for Drug Research Division of Medicinal Chemistry, Vrije Universiteit, Amsterdam, 1081 HV, Neth.
SO European Journal of Medicinal Chemistry (**1997**), 32(2), 95-102
CODEN: EJMCA5; ISSN: 0223-5234
PB Elsevier
DT Journal
LA English
OS CASREACT 126:301606
AB A novel series of cyproheptadine derivs., in which an amino acid or a dipeptide moiety was introduced at the piperidine nitrogen, have been synthesized. The amino acid and dipeptide moieties were taken as part of leukotriene D4 (LTD4) pharmacophore. This modification reduced the H1-antihistamine activity (100-1000-fold) but elevated the anti-LTD4 activity (10-100-fold) of the compds., as compared with cyproheptadine. As a result, some of the new compds., especially the α-amino-propionic acid derivs., are well-balanced dual antagonists of histamine and LTD4 with both activities at micromolar range. Radioligand binding studies have confirmed that the new compds., but not cyproheptadine for LTD4, exert their action through competitive occupation of the receptors. One compound, (S)-2-benzyloxycarbonyl-amino-3-[4-(10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5-yloxy)piperidin-1-yl]propionic acid (I), was tested in an in vitro guinea-pig asthma model. It exhibits much more potent inhibition (IC50 = 1.5 μM) against antigen-induced contraction than either terfenadine or FPL55712, the reference drugs. As indicated by an ex vivo binding assay, the drug I does not readily pass the blood-brain barrier, and therefore is unlikely to cause sedating side-effects at a therapeutic dose.
IT **184107-22-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; synthesis and pharmacol. evaluation of amino-acid-containing cyproheptadine derivs. as dual antagonists of histamine H1- and leukotriene D4-receptors in relation to antiasthmatic activity)
RN 184107-22-0 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **184107-25-3P 184107-26-4P**

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(synthesis and pharmacol. evaluation of amino-acid-containing cyproheptadine derivs. as dual antagonists of histamine H1- and leukotriene D4-receptors in relation to antiasthmatic activity)

RN 184107-25-3 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184107-26-4 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **184107-27-5P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(synthesis and pharmacol. evaluation of amino-acid-containing cyproheptadine derivs. as dual antagonists of histamine H1- and leukotriene D4-receptors in relation to antiasthmatic activity)
RN 184107-27-5 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **184107-20-8P 184107-21-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and pharmacol. evaluation of amino-acid-containing cyproheptadine derivs. as dual antagonists of histamine H1- and leukotriene D4-receptors in relation to antiasthmatic activity)
RN 184107-20-8 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184107-21-9 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:743556 CAPLUS
DN 126:18791
TI Preparation of piperidine derivatives as antihistaminic and antileukotriene agents
IN Timmerman, Henk; Zhang, Mingqiang
PA Kowa Co., Ltd., Japan
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 739881	A2	19961030	EP 1996-106213	19960419 <--
	EP 739881	A3	19990203		
	EP 739881	B1	20020306		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08291142	A2	19961105	JP 1995-98797	19950424 <--
	US 5714501	A	19980203	US 1996-634427	19960418 <--
	AT 214050	E	20020315	AT 1996-106213	19960419
	ES 2173993	T3	20021101	ES 1996-106213	19960419
PRAI	JP 1995-98797	A	19950424		

OS MARPAT 126:18791
GI



I



II

AB The title compds. [I; R1, R2 = H; R1R2 = O; R3 = H, R5COOR6, COOR6 (wherein R5 = alkylene, CONH, CONHCH2; R6 = H, lower alkyl); R4 = H, aralkyloxycarbonyl, aminomethylcarbonyl, etc.; A = O, double bond], which showed an antihistaminic and antileukotriene activity, and are useful as preventive and therapeutic agents for asthma and other allergic diseases such as allergic rhinitis, allergic dermatosis and urticaria, were prepared Thus, alkylation of 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine with Me (S)-2-benzyloxycarbonylamino-3-chloropropionate in the presence of NaI, Na2CO3 in Me2CO followed by hydrolysis of the ester group afforded (S)-II which showed 28% inhibition of [3H]LTD4 binding to guinea-pig lung membranes at 10-5 M.

IT **184107-20-8P 184107-21-9P 184107-22-0P**
184107-25-3P 184107-26-4P 184107-37-7P
184107-40-2P 184107-43-5P 184107-47-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperidine derivs. as antihistaminic and antileukotriene

agents)

RN 184107-20-8 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184107-21-9 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184107-22-0 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 184107-25-3 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184107-26-4 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 184107-37-7 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-δ-oxo-γ-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184107-40-2 CAPLUS
CN 1-Piperidinepentanoic acid, γ-amino-4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-δ-oxo-, methyl ester, monohydrobromide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

RN 184107-43-5 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-δ-oxo-γ-[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184107-47-9 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-γ-oxo-β-[[(phenylmethoxy)carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **184107-27-5P 184107-38-8P 184107-41-3P**
184107-44-6P 184107-45-7P 184107-48-0P
184107-49-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine derivs. as antihistaminic and antileukotriene agents)

RN 184107-27-5 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-[[(phenylmethoxy)carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 184107-38-8 CAPLUS

CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-δ-oxo-γ-[[(phenylmethoxy)carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184107-41-3 CAPLUS
CN 1-Piperidinepropanoic acid, α-amino-4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184107-44-6 CAPLUS
CN 1-Piperidinepentanoic acid, γ-amino-4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-δ-oxo-, monohydrobromide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HBr

RN 184107-45-7 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-δ-oxo-γ-[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184107-48-0 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-γ-oxo-β-[[(phenylmethoxy)carbonyl]amino]-, monohydrobromide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184107-49-1 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-γ-oxo-β-[[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:441019 CAPLUS
DN 123:198577
TI Amphoteric drugs. II. Synthesis and antiallergic activity of [4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidino]alkanoic acid derivatives and related compounds
AU Iwasaki, Nobuhiko; Sakaguchi, Jun; Ohashi, Tetsuo; Yamazaki, Masahiro; Ogawa, Nobuo; Yasuda, Shingo; Koshinaka, Eiichi; Kato, Hideo; Ito, Yasuo; Sawanishi, Hiroyuki
CS Res. Dev. Div., Hokuriku Seiyaku Co., Ltd., Fukui, 911, Japan
SO Chemical & Pharmaceutical Bulletin (**1994**), 42(11), 2285-90
CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan
DT Journal
LA English
OS CASREACT 123:198577
GI



I

AB A simple method of transforming classical tricyclic antihistaminics into nonsedative antiallergic agents with equal potency in rats and guinea-pigs is described. A series of [4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidino]alkanoic acid derivs. [I, X = CH:CH, CH2CH2, CH2O, CH2S, O, S, H,H; R = CH2CO2H, CH2CH2CO2H, (CH2)4CO2H, (CH2)5CO2H] were synthesized and examined for antiallergic and antihistaminic activities and effects on the central nervous system (CNS) in comparison with the corresponding N-Me derivs. (I, same X; R = Me). N-alkylcarboxylic acids showed stronger inhibitory effects on 48 h homologous passive cutaneous anaphylaxis (PCA) in rats than the N-Me derivs., and also were less effective in prolongation of the sleeping time on hexobarbital-induced anesthesia in mice. Introduction of an oxygen atom into the central ring of the tricyclic system in amphoteric compds. enhanced their antiallergic and antihistaminic activities. 3-[4-(6H-dibenz[b,e]oxepin-11-ylidene)piperidino]propionic acid (I, X = CH2O; R = CH2CH2CO2H) exhibited strong inhibitory effects on 48 h homologous PCA in rats (ED50 = 0.067 mg/kg, p.o.) and on histamine-induced bronchoconstriction in anesthetized guinea-pigs (ED50 = 0.0085 mg/kg, p.o.), and thus is a promising candidate as an antiallergic agent.

IT **134204-67-4P 134204-70-9P 134204-72-1P**
134204-74-3P 134204-75-4P 134204-76-5P
134204-78-7P 138248-18-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antiallergic and antihistaminic activity of (dibenzocycloheptenylidenepiperidino)alkanoic acids and related compds.)

RN 134204-67-4 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)- (9CI) (CA INDEX NAME)



RN 134204-70-9 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



RN 134204-72-1 CAPLUS
CN 1-Piperidineacetic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-74-3 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-75-4 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-76-5 CAPLUS
CN 1-Piperidinehexanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-78-7 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)- (9CI) (CA INDEX NAME)



RN 138248-18-7 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **134204-46-9P 134204-50-5P 134204-52-7P**
134204-54-9P 134204-55-0P 134204-58-3P
134204-66-3P 138248-29-0P 167564-81-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antiallergic and antihistaminic activity of (dibenzocycloheptenylidenepiperidino)alkanoic acids and related compds.)

RN 134204-46-9 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-50-5 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



RN 134204-52-7 CAPLUS
CN 1-Piperidineacetic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 134204-54-9 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 134204-55-0 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-58-3 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-66-3 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 138248-29-0 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



RN 167564-81-0 CAPLUS
CN 1-Piperidinehexanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:270113 CAPLUS
DN 120:270113
TI Preparation of piperidine derivatives as antiarrhythmics
IN Hirasawa, Akira; Suzuki, Noboru; Yoshimoto, Ryota; Suzuki, Nobuyasu; Kanematsu, Akira; Shoji, Masataka
PA Ajinomoto KK, Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05097808	A2	19930420	JP 1991-260838	19911008 <--
	JP 2961995	B2	19991012		
PRAI	JP 1991-260838		19911008		

OS MARPAT 120:270113
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB QXm(CR1:CR2)nCH2A [I; A = organic group Q1 (wherein Z = CH2, O, S), Q2 (wherein Z1 = O, S, CH:CH), Q3, Q4; R1, R2 = H, Me, Et; m, n = 0,1; Q = (un)substituted Ph, pyridyl, tetrahydropyranyl, cyclohexyl, piperidinyl, or indanyl; X = (CH2)k (wherein k = 0-3), NHCO(CH2)k, CO(CH2)k] are prepared Thus, chlorination of 4-(1-imidazolylmethyl)cinnamic alc. with SOCl2 in CHCl3 and condensation of the resulting 4-(1-imidazolylmethyl)cinnamyl chloride with 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine in the presence of K2CO3 and NaI in iso-BuCOMe at 90° gave 36.1% title compound II (R3 = 1-imidazolylmethyl). A total of 72 I were prepared and II (R3 = CF3CONH), at 100 μg/kg i.v., inhibited the arrhythmia induced by adrenaline (2.5-5 μg/kg) in dogs by 100% after 15 min.

IT **152930-66-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiarrhythmic piperidine derivative)

RN 152930-66-0 CAPLUS

CN 1-Piperidinebutanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)- (9CI) (CA INDEX NAME)



L10 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:83546 CAPLUS
DN 116:83546
TI Preparation of ω-[4-[(hetero)arylidine]piperidino]alkanoates as antiallergic and antihistaminic agents
IN Ito, Yasuo; Kato, Hideo; Koshinaka, Eiichi; Ogawa, Nobuo; Nishino, Hiroyuki; Sakaguchi, Jun
PA Hokuriku Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 451772	A1	19911016	EP 1991-105567	19910409 <--
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	JP 03294277	A2	19911225	JP 1990-93968	19900411 <--
	JP 04001193	A2	19920106	JP 1990-97522	19900416 <--
	CA 2038417	AA	19911012	CA 1991-2038417	19910315 <--
PRAI	JP 1990-93968	A	19900411		
	JP 1990-97522	A	19900416		

OS MARPAT 116:83546
GI



AB Title compds. [I; A = (hetero)arylidene groups Q1, Q2; R = H, alkyl; X = CH2S, S; Y = alkylene] were prepared Thus, 4-(9H-thioxanthen-9-cyclidene)piperidine (preparation given) was condensed with Br(CH2)3CO2Et to give, after saponification, I (A = Q2, R = H, X = S) [II; Y = (CH2)3]. II (Y = CH2CH2) gave 96% inhibition of passive cutaneous anaphylaxis in rats at 1 mg/kg orally.

IT **138248-29-0P 138248-31-4P 138248-32-5P**
138248-33-6P 138248-34-7P 138248-35-8P
138248-36-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiallergics and antihistaminics)

RN 138248-29-0 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



RN 138248-31-4 CAPLUS
CN 1-Piperidineacetic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



RN 138248-32-5 CAPLUS
CN 1-Piperidinebutanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



RN 138248-33-6 CAPLUS
CN 1-Piperidinepentanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138248-34-7 CAPLUS
CN 1-Piperidinehexanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138248-35-8 CAPLUS
CN 1-Piperidineheptanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138248-36-9 CAPLUS
CN 1-Piperidineoctanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **138248-18-7P 138248-20-1P 138248-21-2P**
138248-22-3P 138248-23-4P 138248-39-2P
138248-40-5P 138272-00-1P 138272-01-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiallergic and antihistaminic)
RN 138248-18-7 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138248-20-1 CAPLUS
CN 1-Piperidineacetic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



RN 138248-21-2 CAPLUS
CN 1-Piperidinehexanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138248-22-3 CAPLUS
CN 1-Piperidineheptanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138248-23-4 CAPLUS
CN 1-Piperidineoctanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138248-39-2 CAPLUS
CN 1-Piperidineheptanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



RN 138248-40-5 CAPLUS

CN 1-Piperidineoctanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



RN 138272-00-1 CAPLUS
CN 1-Piperidinebutanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 138272-01-2 CAPLUS
CN 1-Piperidinepentanoic acid, 4-dibenzo[b,e]thiepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:408587 CAPLUS
DN 115:8587
TI Preparation of 4-[5H-dibenzo[a,d]cyclohepten-5-ylidene]-1-piperidinealkanoates and analogs as antiallergics and antihistaminics
IN Itoh, Yasuo; Kato, Hideo; Koshinaka, Eiichi; Nishino, Hiroyuki; Sakaguchi, Jun
PA Hokuriku Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 406739	A2	19910109	EP 1990-112533	19900630 <--
	EP 406739	A3	19920226		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 03128354	A2	19910531	JP 1990-92194	19900409 <--
	CA 2018942	AA	19910104	CA 1990-2018942	19900613 <--
	AU 9056993	A1	19910110	AU 1990-56993	19900613 <--
	AU 620996	B2	19920227		
	US 5095022	A	19920310	US 1990-538085	19900613 <--
	ZA 9004665	A	19910424	ZA 1990-4665	19900615 <--
	HU 54645	A2	19910328	HU 1990-4076	19900703 <--
PRAI	JP 1989-171090	A	19890704		
	JP 1990-92194	A	19900409		

OS MARPAT 115:8587
GI



I

AB The title compds. [I; R = H, alkyl; X = CH:CH, CH2CH2, CH2O; Y = (O-interrupted) alkylene] were prepared Thus, 4-[5H-dibenzo[a,d]cyclohepten-5-ylidene]piperidine (preparation given) was condensed with CH2:CHCO2Et to give, after saponification, I (R = H, X = CH:CH, Y = CH2CH2) which gave 91% inhibition of passive cutaneous anaphylaxis in rats at 1 mg/kg orally.
IT **134204-46-9P 134204-49-2P 134204-50-5P**
134204-51-6P 134204-52-7P 134204-53-8P
134204-54-9P 134204-55-0P 134204-56-1P
134204-57-2P 134204-58-3P 134204-59-4P
134204-61-8P 134204-62-9P 134204-64-1P
134204-65-2P 134204-66-3P 134204-67-4P
134204-69-6P 134204-70-9P 134204-71-0P
134204-72-1P 134204-73-2P 134204-74-3P
134204-75-4P 134204-76-5P 134204-77-6P
134204-78-7P 134204-79-8P 134204-81-2P
134204-83-4P 134204-84-5P 134204-85-6P
134204-88-9P 134204-89-0P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as antiallergic and antihistaminic)

RN 134204-46-9 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-49-2 CAPLUS

CN 1-Piperidinebutanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-50-5 CAPLUS

CN 1-Piperidinepropanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



RN 134204-51-6 CAPLUS
CN 1-Piperidinepentanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-52-7 CAPLUS
CN 1-Piperidineacetic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 134204-53-8 CAPLUS
CN 1-Piperidineacetic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-methyl-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-54-9 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 134204-55-0 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-56-1 CAPLUS
CN 1-Piperidinehexanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-57-2 CAPLUS
CN 1-Piperidineacetic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-58-3 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-59-4 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-61-8 CAPLUS
CN 1-Piperidineacetic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-62-9 CAPLUS
CN 1-Piperidinebutanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-64-1 CAPLUS
CN 1-Piperidinehexanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-65-2 CAPLUS
CN 1-Piperidinehexanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-66-3 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 134204-67-4 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)- (9CI) (CA INDEX NAME)



RN 134204-69-6 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-70-9 CAPLUS
CN 1-Piperidinepropanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



RN 134204-71-0 CAPLUS
CN 1-Piperidinepentanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-72-1 CAPLUS
CN 1-Piperidineacetic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-73-2 CAPLUS
CN 1-Piperidineacetic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-α-methyl- (9CI) (CA INDEX NAME)



RN 134204-74-3 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-75-4 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-,

hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-76-5 CAPLUS
CN 1-Piperidinehexanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-77-6 CAPLUS
CN 1-Piperidineacetic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-78-7 CAPLUS
CN 1-Piperidinepropanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)- (9CI) (CA INDEX NAME)



RN 134204-79-8 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-81-2 CAPLUS
CN 1-Piperidinebutanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-83-4 CAPLUS
CN 1-Piperidinehexanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-84-5 CAPLUS
CN 1-Piperidineacetic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene- (9CI) (CA INDEX NAME)



RN 134204-85-6 CAPLUS
CN 1-Piperidinehexanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 134204-88-9 CAPLUS
CN 1-Piperidinebutanoic acid, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 134204-89-0 CAPLUS
CN 1-Piperidinepentanoic acid, 4-dibenz[b,e]oxepin-11(6H)-ylidene-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:437748 CAPLUS
DN 109:37748
TI Preparation of 2-chloro-11-[1-[(2-decanoyloxy)ethyl]-4-piperidinylidene]-6,11-dihydrodibenzo[b,e]-thiepin with dopaminomimetic and antiparkinsonism effects
IN Protiva, Miroslav; Bartl, Vaclav; Dlabac, Antonin; Valchar, Martin
PA Czech.
SO Czech., 3 pp.
CODEN: CZXXA9
DT Patent
LA Czech
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CS 235173	B1	19850515	CS 1983-7814	19831024 <--
PRAI CS 1983-7814		19831024		

OS CASREACT 109:37748
GI



I, R=OC(CH2)8Me
II, R=H

AB The title compound (I) is prepared by esterification of II or its HCl salt with decanoyl chloride or decanoic acid. I exhibits a mild prolonged dopaminomimetic activity and can be considered for parkinsonism therapy. II.HCl was prepared from 2-chloro-11-(1-methyl-4-piperidinylidene)-6,11-dihydrodibenzo[b,e]thiepin via 2-chloro-11-(1-ethoxycarbonylmethyl-4-piperidinylidene)-6,11-dihydrodibenzo[b,e]thiepin and 2-chloro-11-(4-piperidinylidene)-6,11-dihydrodibenzo[b,e]thiepin. A suspension of 11.8 g II-HCl in 100 mL water was alkalized with excess NH4OH, and II was extracted with benzene. After removal of benzene, the residue was dissolved in a mixture containing 20 mL CHCl3 and 70 mL benzene and 13.8 g decanoyl chloride was added. After holding overnight at room temperature the reaction mixture was diluted with CHCl3, washed with water and 5% NaOH, dried, and concentrated in vacuum. The residue was diluted in ligroin and purified by column chromatog. on Al2O3 to give 8.8 g I. The yield was 58%. At 5 mg/kg in dogs, I did not prevent apomorphine-induced emesis. However after 1 or 2 wk I increased significantly emetic effect of apomorphine. I decreased the cataleptic effect of perphenazine by 20%. At 50 mg/kg, I decreased the level of homovanillic acid in rat brain by 58% for 5 days.

IT **113982-72-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and decarboxylation of)

RN 113982-72-2 CAPLUS

CN 1-Piperidineacetic acid, 4-(2-chlorodibenzo[b,e]thiepin-11(6H)-ylidene)-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:186304 CAPLUS

DN 104:186304

TI 4-(5H-Dibenzo[a,d]cyclohepten-5-yl)piperidine compounds

IN Young, Steven D.
PA Merck and Co., Inc. , USA
SO Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 157399	A2	19851009	EP 1985-103884	19850401 <--
	EP 157399	A3	19860205		
	EP 157399	B1	19890816		
	R: CH, DE, FR, GB, IT, LI, NL				
	US 4758577	A	19880719	US 1984-596958	19840405 <--
	JP 60231652	A2	19851118	JP 1985-71332	19850405 <--
PRAI	US 1984-596958	A	19840405		

OS CASREACT 104:186304; MARPAT 104:186304
GI For diagram(s), see printed CA Issue.
AB Piperidines I [Δ10 present or absent; R = (CH2)nC6H4R4 (n = 1-3, R4 = dialkylamine, alkoxy), CH2CH:CHC6H5-mR5m (m = 0-3, R5 = alkoxy), CH2CH2R6 (R6 = cyano, CONH2, CH2NH2), COR1 [R1 = (un)substituted alkyl, Ph, or styryl], C(:NH)NH2, CH:Z (Z = O, S), SO2R2 (R2 = alkyl), Q (dashed line = residue of a heterocyclic ring); R3 = H, halo, CF3, alkoxy], useful as inhibitors of Ca-induced contraction of tracheal smooth muscle or vascular tissue, were prepared A mixture of I (Δ10 present, R = R3 = H), 4-Me2NC6H4CHO, NaB(CN)H3, and EtOH was stirred 24 h at room temperature to give I (R = 4-Me2NC6H4CH2) which, at 10-7 M, showed 69% inhibition of Ca-induced contraction described above. The most effective compds. for this inhibition were those in which the C of the R group attached to the piperidine N at the point of attachment is in the reduced form, e.g., CH2R7 (R7 = remainder of substituent). The most active compds. are those where the C of R7 attached to the reduced C was part of an unsatd. grouping.
IT **101904-65-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as inhibitor of calcium-induced contraction of smooth muscle or vascular tissue)
RN 101904-65-8 CAPLUS
CN 1-Piperidinepentanoic acid, 4-(5H-dibenzo[a,d]cyclohepten-5-yl)-δ-oxo- (9CI) (CA INDEX NAME)